Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04095156

Autoreactive B Cells in Membranous Nephropathy

PLA2R Autoreactive B-Cell Subsets and Immune Cell Monitoring in Membranous Nephropathy: Identification of Outcome Predictors and Novel Insights Into Disease Pathogenesis

Status
Recruiting
Phase
Study type
Observational
Enrollment
86 (estimated)
Sponsor
Mario Negri Institute for Pharmacological Research · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome (NS) in adults. The majority of MN patients show detectable circulating antibodies against the M-type phospholipase A2 receptor (PLA2R). Infusion of anti-CD20 monoclonal antibodies results in a profound depletion of B-cells, which are thought to be responsible for anti-PLA2R production. B-cell depletion is followed by NS remission in 70% of cases. Limited evidence highlighted that differences in the B- and T-cell compartments may exist between responders and non-responders. Owing to the non-homogenous efficacy of anti-CD20 treatment, investigators hypothesize that in MN patients who experience NS remission after B-cell depleting therapy, autoreactive B-cells may be mostly circulating, whereas in patients who do not respond to the same treatment, autoreactive B-cells may chiefly reside into secondary lymphoid organs - and thus be more resistant to the drug action. Researchers will therefore extensively analyze the circulating immune repertoire of MN patients before and after the infusion of B-cell lineage depleting agents, assessing the presence of circulating PLA2R autoreactive B cells from appropriately stratified responder and non-responder patients. Patients and healthy controls will be enrolled in this study. Patients will be stratified according to gender, anti-PLA2R status, type of B-cell lineage depleting agent received and response to treatment.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTIn vitro assays.Biochemical and flow-cytometry analysis of specimen collected.

Timeline

Start date
2019-09-25
Primary completion
2026-11-01
Completion
2026-11-01
First posted
2019-09-19
Last updated
2026-03-20

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT04095156. Inclusion in this directory is not an endorsement.